{"id":49039,"date":"2022-09-30T17:01:52","date_gmt":"2022-09-30T15:01:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/insights-on-the-reiters-syndrome-treatment-global-market-to-2027-rapidly-increasing-reactive-arthritis-incidences-and-rising-demand-for-effective-treatment-are-expected-to-drive-growth-researchan\/"},"modified":"2022-09-30T17:01:52","modified_gmt":"2022-09-30T15:01:52","slug":"insights-on-the-reiters-syndrome-treatment-global-market-to-2027-rapidly-increasing-reactive-arthritis-incidences-and-rising-demand-for-effective-treatment-are-expected-to-drive-growth-researchan","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/insights-on-the-reiters-syndrome-treatment-global-market-to-2027-rapidly-increasing-reactive-arthritis-incidences-and-rising-demand-for-effective-treatment-are-expected-to-drive-growth-researchan\/","title":{"rendered":"Insights on the Reiter’s Syndrome Treatment Global Market to 2027 – Rapidly Increasing Reactive Arthritis Incidences and Rising Demand for Effective Treatment are Expected to Drive Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Reiter’s Syndrome Treatment Market – Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Drug Type, Immunosuppressive Drugs, Others, By Dosage Form, By Route of Administration, By Distribution Channel, By End User, By Region”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global Reiter’s syndrome treatment market is anticipated to grow at a significant CAGR during the forecast period, 2023-2027. The market growth can be attributed to the rising instances of reactive arthritis and advancements in treatment processes and methods.\n<\/p>\n

\nBesides, advances in the healthcare industry have led to better accessibility of patient care suffering from severe conditions like reactive arthritis, contributing to the growth of the global Reiter’s syndrome treatment market.\n<\/p>\n

\nReiter’s syndrome is a type of inflammatory arthritis, which is also known as reactive arthritis. The painful inflammation is caused by a bacterial infection. These bacteria are frequently found in the genital tract, such as Chlamydia trachomatis, or the bowel, such as Campylobacter, Salmonella, Shigella, and Yersinia. Genital bacteria spread through sex and usually causes no noticeable symptoms. A pus-like or watery discharge from the genitals is observed in some cases. Bowel bacteria, on the other hand, usually cause diarrhea along with discharge and can be considered minor symptom of Reiter’s syndrome.\n<\/p>\n

\nRapidly increasing reactive arthritis incidences and rising demand for effective treatment are expected to drive the global Reiter’s syndrome treatment market over the next five years. When compared to other types of arthritis, reactive arthritis is a rare form. As of 2021, more than 350 million arthritis patients are affected by Reiter’s syndrome. According to the CDC, arthritis affects 24% of all adults in the United States, approx. 58.5 million people. One in every four adults has arthritis and suffers from severe joint pain.\n<\/p>\n

\nReiter’s syndrome affects approximately 27 per 100,000 people worldwide, with adult males aged 20 to 40 most affected. Growing population, rising instances of unprotected sexual intercourse increase the population’s chances of contracting the disease and assist in the growth of the global Reiter’s syndrome treatment market over the next five years.\n<\/p>\n

\nYears considered for this report:<\/strong>\n<\/p>\n